Literature DB >> 16227638

Neuroprotective properties of statins.

Karolina Stepień1, Michał Tomaszewski, Stanisław J Czuczwar.   

Abstract

Treatment with statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) reduces the risk of ischemic stroke among patients with increased risk of vascular disease. Recent experimental data point to neuroprotective properties of statins in acute cerebral ischemia. There is a proven link between bioavailability of nitric oxide and the activity of statins and ischemic stroke. Due to their ability to up-regulate nitric oxide synthase, statins have been considered in the therapy of a number of the central nervous system disorders, including cerebral ischemia, Alzheimer's disease, Parkinson's disease, tumors, and trauma. It has been claimed that they suppress inflammatory response and secondary injury after acute ischemia.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16227638

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN： 1734-1140            Impact factor:   3.024


  22 in total

1.  Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease.

Authors:  Xuemei Huang; Honglei Chen; William C Miller; Richard B Mailman; Jennifer L Woodard; Peter C Chen; Dong Xiang; Richard W Murrow; Yi-Zhe Wang; Charles Poole
Journal:  Mov Disord       Date:  2007-02-15       Impact factor: 10.338

2.  Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.

Authors:  Claudia Becker; Susan S Jick; Christoph R Meier
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 3.  Role of HMG-CoA reductase inhibitors in neurological disorders : progress to date.

Authors:  Allison B Reiss; Elzbieta Wirkowski
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Statin use and Parkinson's disease in Denmark.

Authors:  Beate Ritz; Angelika D Manthripragada; Lei Qian; Eva Schernhammer; Lene Wermuth; Jorgen Olsen; Soren Friis
Journal:  Mov Disord       Date:  2010-07-15       Impact factor: 10.338

5.  Statin-induced T-lymphocyte modulation and neuroprotection following experimental subarachnoid hemorrhage.

Authors:  Robert E Ayer; Robert P Ostrowski; Takashi Sugawara; Qingy Ma; Nazanin Jafarian; Jiping Tang; John H Zhang
Journal:  Acta Neurochir Suppl       Date:  2013

Review 6.  Statins and neuroprotection: a prescription to move the field forward.

Authors:  W Gibson Wood; Gunter P Eckert; Urule Igbavboa; Walter E Müller
Journal:  Ann N Y Acad Sci       Date:  2010-06       Impact factor: 5.691

7.  Antihyperalgesic and anti-inflammatory effects of atorvastatin in chronic constriction injury-induced neuropathic pain in rats.

Authors:  Nitya N Pathak; Venkanna Balaganur; Madhu C Lingaraju; Amar S More; Vinay Kant; Dhirendra Kumar; Dinesh Kumar; Surendra Kumar Tandan
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

8.  Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake.

Authors:  Tetsadê C B Piermartiri; Samuel Vandresen-Filho; Bruno de Araújo Herculano; Wagner C Martins; Denis Dal'agnolo; Ellen Stroeh; Cristiane Lima Carqueja; Carina R Boeck; Carla I Tasca
Journal:  Neurotox Res       Date:  2009-05-02       Impact factor: 3.911

9.  Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.

Authors:  Xuemei Huang; Peggy Auinger; Shirley Eberly; David Oakes; Michael Schwarzschild; Alberto Ascherio; Richard Mailman; Honglei Chen
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

10.  Cholesterol-lowering drugs and incident open-angle glaucoma: a population-based cohort study.

Authors:  Michael W Marcus; Rogier P H M Müskens; Wishal D Ramdas; Roger C W Wolfs; Paulus T V M De Jong; Johannes R Vingerling; Albert Hofman; Bruno H Stricker; Nomdo M Jansonius
Journal:  PLoS One       Date:  2012-01-04       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.